Welcome to our dedicated page for Establishment Labs Hldgs news (Ticker: ESTA), a resource for investors and traders seeking the latest updates and insights on Establishment Labs Hldgs stock.
Establishment Labs Holdings Inc. develops and markets medical technology for women’s health, principally breast aesthetics and reconstruction. The company’s recurring news covers Motiva implants and related minimally invasive platform activity, global product adoption, U.S. and outside-the-U.S. commercialization, and sales channels serving distributors, physicians, hospitals, and clinics.
Updates also include quarterly and annual financial results, revenue guidance, operating expense leverage, adjusted EBITDA commentary, credit-facility refinancing, leadership changes, and health care conference participation. Product and market updates commonly center on the Motiva portfolio, silicone-filled breast and body-shaping implants, and expansion across Europe, Latin America, Asia-Pacific/Middle East, and other markets.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) officially launched its Motiva Flora® tissue expander in Europe during a symposium at the London Breast Meeting on September 2, 2021. This RFID-enabled device aims to enhance post-mastectomy reconstruction, improving patient comfort through advanced biocompatibility and MRI imaging capabilities. CEO Juan José Chacón-Quirós highlighted the significance of Flora in capturing a substantial market share in breast reconstruction, projecting improved outcomes for women. Motiva Flora is not yet approved for distribution in the U.S.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) has announced the launch of Motiva Flora®, a new tissue expander in Europe and CE Mark countries, set for September 2, 2021. This innovative product features patented SmoothSilk® surface technology and RFID-enabled ports, aiming to enhance imaging and patient outcomes. The event will include presentations from medical professionals and discussion on commercialization plans. Currently, Motiva Flora is not approved for distribution in the U.S.
Summary not available.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) has announced participation in the UBS Genomics 2.0 and MedTech Innovations Summit from August 10-12, 2021. CEO Juan José Chacón-Quirós and Interim CFO Raj Denhoy will address attendees on August 12 at 8:00 am ET. A live webcast of their presentation will be available on the company's investor relations website, along with an archived version post-event. Establishment Labs specializes in women's health, notably breast aesthetics and reconstruction, marketing over 1.6 million Motiva Implants® worldwide since 2010.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) reported a second-quarter revenue of $32.0 million, up 205% year-over-year, achieving a quarterly record. The company raised its 2021 revenue guidance to $122 million to $126 million, a 44% to 49% increase from 2020. Operating expenses rose to $26.1 million, up 55% from the previous year, contributing to a net loss of $5.3 million. The company maintains a cash balance of $76.8 million. Additionally, notable advancements include the publication of a study on Motiva SmoothSilk implants demonstrating superior biocompatibility.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) announced the publication of its 2020 Corporate Social Responsibility annual review, marking the third anniversary of its NASDAQ listing. CEO Juan José Chacón-Quirós emphasized the company’s commitment to sustainability and governance, alongside financial goals. Key topics included the elevation of Women’s Health as a material focus, the achievement of carbon-neutral certifications, advocacy for women’s health, and highlights of its financial performance. The report aims to align with the 2030 UN Sustainable Development Goals and benchmark against industry peers.
Establishment Labs Holdings (NASDAQ: ESTA) will release its financial results for Q2 2021 on July 29, 2021, prior to market open. A conference call is scheduled for 8:30 am ET the same day to discuss these results. The company specializes in women's health, particularly in breast aesthetics, and offers Motiva Implants®, which are available in over 80 countries. Established in 2018, they received FDA approval for a clinical trial in the U.S. for these implants.
Establishment Labs Holdings (NASDAQ: ESTA) announced the appointment of Ann Custin and Bryan Slotkin to its Board of Directors, effective immediately. Founder and CEO Juan José Chacón-Quirós highlighted their governance experience as crucial for advancing the company's mission in women's health. Custin, former CFO at Siemens Healthineers, and Slotkin, a partner at PJT Partners, bring extensive industry and financial expertise. This leadership change aims to enhance innovation and market expansion, aligning with the company’s commitment to improving women's health through differentiated technology.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) announced CFO Renee Gaeta's departure effective July 30, 2021, with Raj Denhoy appointed as Interim CFO. The company expects second-quarter 2021 revenues between $31 million and $32 million, reflecting a 196% to 206% growth year-over-year. Gaeta expressed gratitude for her tenure, noting the company’s significant growth, including completion of an FDA trial and plans for a third manufacturing facility. Establishment Labs remains committed to its goal of becoming a leader in breast aesthetics and reconstruction.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) has commenced construction on its Sulayöm Innovation Campus in Costa Rica, aimed at enhancing its manufacturing and R&D capabilities in the breast aesthetics market. The project, split into two phases and costing approximately $35 million, is expected to generate up to 1,000 new jobs. The facility will support global growth plans and sustainability initiatives, as the company aims to cater to over half of the worldwide market for Motiva Implants. The groundbreaking marks a significant step in the company’s expansion strategy.